• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Kairos Pharma, Ltd. (KAPA)

Kairos Pharma, Ltd. (KAPA)

Currency in USD Disclaimer

$1.60

$0.1

(6.67%)

Day's range
$1.41
Day's range
$1.87
50-day range
$1.22
Day's range
$4
  • Country: US
  • ISIN: US48301N1046
52 wk range
$1.22
Day's range
$4
  • CEO: Dr. John S. Yu M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score N/A
  • Piotroski Score N/A
  • Grade Buy
  • Symbol (KAPA)
  • Company Kairos Pharma, Ltd.
  • Price $1.60
  • Changes Percentage (6.67%)
  • Change $0.1
  • Day Low $1.41
  • Day High $1.87
  • Year High $4.00

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating N/A
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.21
  • Trailing P/E Ratio -7.91
  • Forward P/E Ratio -7.91
  • P/E Growth -7.91
  • Net Income $0

Income Statement

Quarterly

Annual

Latest News of KAPA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Kairos Pharma, Ltd. Frequently Asked Questions

  • What is the Kairos Pharma, Ltd. stock price today?

    Today's price of Kairos Pharma, Ltd. is $1.60 — it has increased by +6.67% in the past 24 hours. Watch Kairos Pharma, Ltd. stock price performance more closely on the chart.

  • Does Kairos Pharma, Ltd. release reports?

    Yes, you can track Kairos Pharma, Ltd.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Kairos Pharma, Ltd. stock forecast?

    Watch the Kairos Pharma, Ltd. chart and read a more detailed Kairos Pharma, Ltd. stock forecast to see what analysts suggest you do with its shares.

  • What is Kairos Pharma, Ltd. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on AMEX, exchange stock trades by Kairos Pharma, Ltd. stock ticker.

  • How to buy Kairos Pharma, Ltd. stocks?

    Like other stocks, KAPA shares are sold on stock exchanges such as AMEX. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Kairos Pharma, Ltd.'s EBITDA?

    Kairos Pharma, Ltd. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Kairos Pharma, Ltd.’s financial statements.

  • Should I invest in Kairos Pharma, Ltd. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Kairos Pharma, Ltd.'s financials relevant news, and technical analysis. Kairos Pharma, Ltd.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Kairos Pharma, Ltd. stock currently indicates a “sell” signal. For more insights, review Kairos Pharma, Ltd.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.